| Symbol | BIAFW |
|---|---|
| Name | BIOAFFINITY TECHNOLOGIES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Address | 3300 NACOGDOCHES ROAD,SUITE 216, SAN ANTONIO, Texas, 78217, United States |
| Telephone | +1 210 - 698-5334 |
| Fax | — |
| — | |
| Website | https://www.bioaffinitytech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001712762 |
| Description | bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers. Additional info from NASDAQ: |
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Read morebioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Read morebioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Read moreWallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Read morebioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Read morebioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Read more(30% Negative) BIOAFFINITY TECHNOLOGIES, INC. (BIAF) Reports Q3 2026 Financial Results
Read morebioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
Read morebioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07168993 | Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as… | Na | Lung Cancer (Diagnosis) | Recruiting | 2026-02-25 | 2029-07-01 | ClinicalTrials.gov |
| NCT05870592 | Detection of Abnormal Respiratory Cell Populations in Lung Cancer Screening Pat… | — | Lung Cancer | Unknown | 2023-08-01 | 2024-06-01 | ClinicalTrials.gov |
| NCT03457415 | Collection of Sputum and Labeling for Lung Cancer | — | Lung Cancer | Recruiting | 2018-03-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT03837600 | Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCP… | — | Lung Cancer | Completed | 2016-09-22 | 2018-08-15 | ClinicalTrials.gov |
| NCT02388074 | Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP… | Na | Lung Cancer | Completed | 2015-03-01 | 2015-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Standard medical treatment | Drug | Approved | Lung Cancer (Diagnosis) | RECRUITING | NCT07168993 |
| Standard medical treatment | Drug | Approved | Lung Cancer (Diagnosis) | RECRUITING | NCT07168993 |
| CyPath® | Other | Approved | Lung Cancer | COMPLETED | NCT02388074 |
| Standard medical treatment | Drug | Approved | Lung Cancer (Diagnosis) | RECRUITING | NCT07168993 |
| Standard medical treatment | OTHER | Approved | Lung Cancer (Diagnosis) | RECRUITING | NCT07168993 |
| CyPath® | DEVICE | Approved | Lung Cancer | COMPLETED | NCT02388074 |